Climate Change Data

Samsung Bioepis Co., Ltd.

Climate Impact & Sustainability Data (2021-01 to 2022-12, 2023)

Reporting Period: 2021-01 to 2022-12

Environmental Metrics

Total Carbon Emissions:6,087 tCO2e/year (2022)
Scope 1 Emissions:1,139.697 tCO2e/year (2022)
Scope 2 Emissions:4,947.807 tCO2e/year (2022)
Renewable Energy Share:3% (projected for 2023)
Total Energy Consumption:132 TJ/year (2022)
Water Consumption:66,713 tons/year (2022)
Waste Generated:75,599 kg/year (2022)

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Achieved ISO 14001 (environmental management system certification) and ISO 50001 (energy management system certification) in September 2022.
  • Installed 200kW photovoltaic power generators, expected to generate 300MWh per year.
  • Increased the proportion of ocean shipping for drug product/finished drug product (DP/FDP) from 9% in 2021 to 22% in 2022, aiming for 50% in 2025.
  • Reduced energy consumption by implementing various energy-saving measures (LED lights, high-efficiency heating pumps, etc.).
  • Minimized packaging size and used recyclable materials where possible.

Social Achievements

  • Launched various employee wellbeing initiatives, including flexible work arrangements, expanded fringe benefit programs, and a family-friendly business certification.
  • Established a data-driven management system and training programs to support employee growth.
  • Achieved the family-friendly business certification (Jan 2023).
  • Maintained a high employee satisfaction score (94.9% in 2022 for training satisfaction).
  • Reached an estimated 376,000 patients with biosimilars in 2022.

Governance Achievements

  • Established the ESG Office in January 2022 to systematically manage ESG initiatives.
  • Established a professional and diverse board of directors.
  • Implemented a compliance management system to prevent business damage and fulfill social responsibility.
  • Implemented a rigorous quality management system in compliance with global standards.

Climate Goals & Targets

Long-term Goals:
  • Achieve Net Zero emissions by 2050.
Medium-term Goals:
  • Achieve RE100 by 2050.
Short-term Goals:
  • Increase ocean shipping to 50% by 2025.

Environmental Challenges

  • Supply chain disruptions due to unpredictable events (pandemics, natural disasters, geopolitical conflicts).
  • Potential negative environmental impacts from supply chains.
  • Potential negative social impacts from supply chains.
  • Managing climate-related risks (transition risks and physical risks).
Mitigation Strategies
  • Diversifying supply chains to ensure flexible and reliable product supply.
  • Developing a sustainable supply chain policy and updating the Third-Party Code of Conduct.
  • Establishing supply chain ESG assessment processes.
  • Assisting SMEs in bolstering their ESG capabilities.
  • Collaborating with Samsung Biologics to join the Net Zero by 2050 initiative and RE100.
  • Implementing environmental and energy management systems (ISO 14001 and ISO 50001).

Supply Chain Management

Supplier Audits: 18 audits in 2021-2022 (US, Europe, Korea)

Responsible Procurement
  • Third-Party Code of Conduct (CoC)
  • Supply chain ESG assessment process

Climate-Related Risks & Opportunities

Physical Risks
  • Floods
  • Sea level rises
  • Heat waves
  • New infectious diseases
Transition Risks
  • Increasing costs to meet tightening environmental regulations.
Opportunities
  • Expansion into new markets through preemptively responding to tender requirements for environmental sustainability.

Reporting Standards

Frameworks Used: GRI Standards (2021), SASB Standards for Biotechnology & Pharmaceuticals

Certifications: ISO 14001, ISO 50001

Third-party Assurance: Korea Management Registrar Inc.

Sustainable Products & Innovation

  • Eco-friendly packaging

Awards & Recognition

  • 'Company of the Year, Asia-Pacific' Award at the Global Generics & Biosimilars Awards in 2022
  • iF Design Award (Apr 2021)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:6,295 tCO2eq
Scope 1 Emissions:1,209.479 tCO2eq
Scope 2 Emissions:5,085.926 tCO2eq
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Nearly 3%
Total Energy Consumption:138.193 TJ
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:6.2 tCO2eq/KRW 1 billion in 2023

ESG Focus Areas

  • Access to Medicines
  • R&D Innovation
  • Product Quality and Patient Safety
  • Governance
  • Environmental Management
  • Human Rights
  • Supply Chain ESG Risk Management

Environmental Achievements

  • Obtained ISO 14001 (environmental management system) and ISO 50001 (energy management system) certifications.
  • Installed 200kW-capacity photovoltaic power generators, producing 272MWh of power (nearly 3% of annual consumption).
  • Reduced GHG intensity (Scope 1 + Scope 2) from 8.1 tCO2eq/KRW 1 billion in 2021 to 6.2 in 2023.

Social Achievements

  • Hired 91 persons in 2023, with women accounting for over 45% of new hires.
  • Launched a 10-week Health Challenge program, with 99 participants successfully reducing weight and increasing muscular power.
  • Implemented a smoking cessation program with a 97% success rate.
  • Certified as a family-friendly business.

Governance Achievements

  • Established a company-wide risk management system.
  • Obtained ISO 27001 certification for information security management.
  • Established a compliance organization under the CEO's leadership.
  • Maintained 100% director attendance at Board meetings.

Climate Goals & Targets

Long-term Goals:
  • Become Net Zero for Scope 1 & 2 emissions by 2050.
Medium-term Goals:
  • Achieve RE100 for our operations.
Short-term Goals:
  • Reduce emissions from operations by 32% by 2030 from the 2022 base year.

Environmental Challenges

  • Climate-related hazards (cyclones, floods, heatwaves) impacting operations and raw material costs.
  • Rising costs for low-carbon transition.
  • Tightening global regulations on supply chain due diligence.
  • Managing ESG risks along the entire value chain.
Mitigation Strategies
  • Developed business continuity plans and disaster response scenarios.
  • Implemented procedures to respond to extreme heat risks.
  • Established a sustainable supply chain policy and supply chain ESG risk assessment process.
  • Set a 2050 Net Zero goal and a 32% reduction in Scope 1 and 2 emissions by 2030.
  • Joined the RE100 initiative.

Supply Chain Management

Supplier Audits: 22 companies assessed in 2023.

Responsible Procurement
  • Sustainable supply chain policy
  • Third-Party Code of Conduct
  • Regular ESG risk assessments
  • Supply chain diversification

Climate-Related Risks & Opportunities

Physical Risks
  • Cyclones, floods, heatwaves
Transition Risks
  • Rising carbon costs
  • Increasing costs of raw materials
  • Rising costs for low-carbon transition
Opportunities
  • Growing product demand for treatment of climate-related diseases
  • Increased stakeholder communication
  • Use of efficient production processes

Reporting Standards

Frameworks Used: GRI Standards 2021, ISO 26000, UN Global Compact (UNGC), SASB disclosure standards for biotechnology & pharmaceutical sectors, TCFD

Certifications: ISO 14001, ISO 45001, ISO 50001, ISO 27001

Third-party Assurance: Korea Management Registrar Inc.

Sustainable Products & Innovation

  • Eco-friendly packaging

Awards & Recognition

  • Global Generics & Biosimilars Awards 2023 (Company of the Year, Asia Pacific; Regulatory Achievement of the Year)
  • Minister of Science and ICT Award (Excellence in LMO safety management)